Tocilizumab and liver injury in patients with COVID-19

Current mortality rate in patients with COVID-19 disease is about 2%, whereas 5% of patients require admission to the intensive care unit. It is assumed that interleukin (IL)-6 may be involved in the pathogenesis of severe COVID-19 infections; therefore, in the absence of a specific antiviral therap...

Descripción completa

Detalles Bibliográficos
Autores principales: Serviddio, Gaetano, Villani, Rosanna, Stallone, Giovanni, Scioscia, Giulia, Foschino-Barbaro, Maria Pia, Lacedonia, Donato
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Case Series
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7545299/
https://www.ncbi.nlm.nih.gov/pubmed/33101458
http://dx.doi.org/10.1177/1756284820959183

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7545299/
https://www.ncbi.nlm.nih.gov/pubmed/33101458
http://dx.doi.org/10.1177/1756284820959183

Ejemplares similares